PHAnews is meant to give a picture
of recent events
and activities affecting the life of the PH community.
This compilation should not be viewed as endorsement
of the information provided or its accuracy.
Awareness
Month:
Celebrating 15 Years of the PH Community
Each November, the PH community
celebrates PH Awareness Month. This is a special
time to focus our energy around raising awareness
of PH and support for the PH community. This November,
celebrate 15 years of ending isolation and raising
awareness. Participate in one of the activities
found at www.phassociation.org/
Awareness, or create your own!
WASHINGTON - Drugs to treat erectile
dysfunction need stronger warnings on their packaging
about the risk of blindness, U.S. consumer group Public
Citizen said on Thursday in a petition filed with
health regulators.
Pfizer Inc.‘s pulmonary hypertension
drug Revatio, which has the same active ingredient
as its impotence drug Viagra, should also carry a
similar black box warning -- the strongest warning
the agency can require, the advocacy group said.
Surface
Logix completes first human trial for new drug
The Boston company announced
on Tuesday that it finished its first Phase I test for
SLx-2101. The early-stage human clinical trial established
that the drug showed some significant activity in patients
and was also safe and well tolerated at various doses,
the company said.
Surface Logix envisions using the drug
to treat conditions including male erectile dysfunction,
pulmonary arterial hypertension and congestive heart failure.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information
resource for people dealing with PH -- they have ARRIVED
and are ready to ship!!!
The author, a PH patient
herself, knows what it is like to live with the disease.
She talked to many other patients, doctors, and researchers
while writing the Survival Guide. Dr. Ronald J. Oudiz
and a team of physicians with a deep knowledge of
PH edited the book for accuracy.
New edition contains
a chart of 15 drugs used to treat
PH; results of recent clinical trials;
in-depth discussion of PH secondary to other
diseases or conditions; a new chapter on
what to eat if you have PH; and much,
much more!
Encysive
Pharmaceuticals Announces New Thelin™ Data to be Presented
at CHEST 2005
Houston, TX
– October 20, 2005 – Encysive Pharmaceuticals (NASDAQ: ENCY)
today announced that new data from STRIDE-2 and related
clinical trials of Thelin™ (sitaxsentan sodium) in pulmonary
arterial hypertension (PAH) will be presented at the annual
meeting of the American College of Chest Physicians (CHEST),
to be held October 29-November 3 in Montréal.
On
September 27, Senator John Cornyn (R-TX) and Senator Barbara
Mikulski (D-MD) stepped forward to introduce the PH Research
Act in the Senate. The Senate bill follows identical House
legislation which was introduced in June.
Today the House bill has over 237 co-sponsors
standing in support - that's over half of the members of
the House of Representatives, representing over half the
population of the U.S.! Building this kind of support assures
that PH is no longer a marginalized illness. We need your
help to meet that record in the Senate. To date, five senators
have already pledged their support for the PH Research Act.
Join other members of the PH community and ask
for your senators' support (http://www.phassociation.org/Take_Action/).
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
On
September 27, Senator John Cornyn (R-TX) and Senator Barbara
Mikulski (D-MD) stepped forward to introduce the PH Research
Act in the Senate. The Senate bill follows identical House
legislation which was introduced in June. 
